Fulminant myocarditis with myositis after treatment with immune checkpoint inhibitors

被引：0
|
作者：
Vargas-Osorio, K. [1 ]
Prada Ramallal, G. [1 ]
Gonzalez-Ferrero, T. [2 ]
Cameselle-Teijeiro, J. M. [1 ,3 ,4 ]
机构：
[1] Clin Univ Hosp Santiago, Pathol Serv, La Coruna, Spain
[2] Univ Hosp Lucus Augusti, Serv Cardiol, Lugo, Spain
[3] Hlth Res Inst Santiago de Compostela IDIS, La Coruna, Spain
[4] Univ Santiago de Compostela, Dept Pathol, La Coruna, Spain
来源：
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY | 2024年 / 135卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
12
引用
收藏
页码：26 / 27
页数：2
相关论文
共 50 条
  • [41] Myocarditis: Uncommon but severe toxicity of immune checkpoint inhibitors
    Courand, Pierre-Yves
    Bouali, Anissa
    Harbaoui, Brahim
    Cautela, Jennifer
    Thuny, Franck
    Lantelme, Pierre
    BULLETIN DU CANCER, 2019, 106 (11) : 1050 - 1056
  • [42] Myasthenia gravis, myositis and myocarditis: a fatal triad of immune-related adverse effect of immune checkpoint inhibitor treatment
    Soman, Biji
    Dias, Maria Cecilia
    Rizvi, Syed Azhar J.
    Kardos, Attila
    BMJ CASE REPORTS, 2022, 15 (12)
  • [43] Successful treatment of immune checkpoint inhibitor-associated fulminant myocarditis with abatacept and ruxolitinib: a case report
    Wadden, Elena
    Lai, Carol
    Grivas, Petros
    Bhatia, Shailender
    Portuguese, Andrew J.
    Salem, Joe-Elie
    Moslehi, Javid J.
    Cheng, Richard K.
    EUROPEAN HEART JOURNAL-CASE REPORTS, 2025, 9 (02)
  • [44] Fulminant myocarditis with myositis of ocular and respiratory muscles
    Hiraiwa, Hiroaki
    Furusawa, Kenji
    Kazama, Shingo
    Kimura, Yuki
    Shibata, Naoki
    Arao, Yoshihito
    Oishi, Hideo
    Kato, Hiroo
    Kuwayama, Tasuku
    Yamaguchi, Shogo
    Kondo, Toru
    Sawamura, Akinori
    Morimoto, Ryota
    Okumura, Takahiro
    Murohara, Toyoaki
    NAGOYA JOURNAL OF MEDICAL SCIENCE, 2020, 82 (03): : 585 - 593
  • [45] FULMINANT MYOCARDITIS AS A COMPLICATION OF SCLERODERMA PATIENTS WITH MYOSITIS
    KERR, LD
    SPIERA, H
    ARTHRITIS AND RHEUMATISM, 1992, 35 (09): : S237 - S237
  • [46] Troponin Kinetics and Cardiovascular Events in Patients With Myocarditis After Immune Checkpoint Inhibitors Use
    Silva, Thiago
    Drobni, Zsofia
    Zafar, Amna
    Gongora, Carlos
    Zubiri, Leyre
    Zlotoff, Daniel
    Gong, Jingyi
    Lee, Charlotte
    Hartmann, Sarah
    Gilman, Hannah
    Villani, Alexandra-Chloe
    Sullivan, Ryan
    Reynolds, Kerry
    Zhang, Lili
    Nohria, Anju
    Neilan, Tomas
    CIRCULATION, 2021, 144
  • [47] Fulminant Immune-mediated Myocarditis in a Metastatic Cancer Patient on Combination Therapy of TIGIT and PD-1 Immune Checkpoint Inhibitors
    Fallahi, Sara
    Kraus, Samuel
    Abdelaziz, Ahmed
    Parks, Bruce
    LABORATORY INVESTIGATION, 2024, 104 (03) : S12 - S13
  • [48] IMMUNE CHECKPOINT INHIBITOR-RELATED MYASTHENIA GRAVIS, MYOSITIS, HEPATITIS, AND MYOCARDITIS
    Pham, Phuoc
    Heppler, Miranda
    Jackson, Ian P.
    Plambeck, Robert W.
    CHEST, 2024, 166 (04) : 5381A - 5382A
  • [49] Fulminant Myocarditis Caused by an Immune Checkpoint Inhibitor: A Case Report With Pathologic Findings
    Imai, Ryosuke
    Ono, Masafumi
    Nishimura, Naoki
    Suzuki, Koyu
    Komiyama, Nobuyuki
    Tamura, Tomohide
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (02) : E36 - E38
  • [50] Methylprednisolone/pembrolizumabLack of efficacy, immune checkpoint inhibitors-induced interstitial lung disease and fulminant myocarditis: case report
    Reactions Weekly, 2024, 2023 (1) : 241 - 241
12345